TY  - JOUR

T1  - Immunogenicity and safety of AZD2816, a beta (B.1.351) variant COVID-19 vaccine, and AZD1222 (ChAdOx1 nCoV-19) as third-dose boosters for previously vaccinated adults: a multicentre, randomised, partly double-blinded, phase 2/3 non-inferiority immunobridging study in the UK and Poland

JO  - The Lancet Microbe

UR  - http://dx.doi.org/10.1016/s2666-5247(23)00177-5

PY  - 2023/09/29

AU  - Ramasamy MN

AU  - Kelly EJ

AU  - Seegobin S

AU  - Dargan PI

AU  - Payne R

AU  - Libri V

AU  - Adam M

AU  - Aley PK

AU  - Martinez-Alier N

AU  - Church A

AU  - Jepson B et al

ED  - 

DO  - DOI: 10.1016/s2666-5247(23)00177-5

PB  - Elsevier BV

VL  - 4

IS  - 11

SP  - e863

EP  - e874

Y2  - 2024/12/22

ER  -